USPTO Patent Application for Tyk2 Inhibitor Dosage Forms
Summary
The USPTO has published a patent application (US20260083734A1) for novel dosage forms of Tyk2 inhibitors, specifically BMS-986165, intended for treating autoimmune and inflammatory diseases. The application details stable and bioavailable formulations, including spray-dried dispersions in a polymer matrix.
What changed
This document is a USPTO patent application (US20260083734A1) filed on December 2, 2025, for "Dosage Forms for Tyk2 Inhibitors." The application describes stable and bioavailable formulations, including spray-dried dispersions, of a specific Tyk2 inhibitor (BMS-986165) in a solid polymer matrix. These formulations are intended for the treatment of autoimmune and auto-inflammatory diseases such as inflammatory bowel disease and psoriasis.
As this is a patent application, it does not impose direct compliance obligations on pharmaceutical companies. However, it signifies potential future intellectual property protection and innovation in the treatment of autoimmune diseases. Companies operating in this space should monitor patent filings for competitive intelligence and potential licensing opportunities.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
DOSAGE FORMS FOR TYK2 INHIBITORS
Application US20260083734A1 Kind: A1 Mar 26, 2026
Inventors
Sherif Ibrahim Farag Badawy, Jonathan R. Brown, Candice Y. Choi, Christoph Gesenberg, Vivienne Gray, John Wynne Jones, Umesh Kestur, Balvinder S. Vig, Xiaotian S. Yin, Christopher A. Zordan, Corey Bloom, Ian Yates
Abstract
Stable and bioavailable formulations and dosage forms comprising a dispersion (e.g., spray-dried dispersion) of solid amorphous 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (Formula (I); BMS-986165) in a solid polymer matrix are provided for the treatment of auto-immune and auto-inflammatory diseases such as an inflammatory bowel disease (IBD) and psoriasis:
CPC Classifications
A61K 31/501 A61K 9/0053 A61K 9/2009 A61K 9/2013 A61K 9/2018 A61K 9/2054 A61K 9/284 A61K 45/06
Filing Date
2025-12-02
Application No.
19406929
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.